The Marfan syndrome

Israel Medical Association Journal

Volumn 10, Issue 3, 2008, Pages 175-178

  Frydman, Moshe ^a,b  

^a GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Aortic tear; Dural ectasia; Ectopia lentis; FBN1 gene; Fibrillin 1; Kyphoscoliosis; Marfan syndrome

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRILLIN 1; WARFARIN;

AORTA DISSECTING ANEURYSM; ARTERY DILATATION; ARTICLE; ASTIGMATISM; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE CLASSIFICATION; DURAL ECTASIA; FUNNEL CHEST; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MARFAN SYNDROME; MUSCULOSKELETAL DISEASE; MYOPIA; PNEUMOTHORAX; PREGNANCY; SCOLIOSIS; STRIA;

HUMANS; MARFAN SYNDROME; MICROFILAMENT PROTEINS;

EID: 43249092902     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. McKusick VA. The cardiovascular aspects of Marfan's syndrome. Circulation. 1955;11:321-42.
2. Pyeritz RE. Marfan syndrome and other disorders of fibrillin. In: Rimoin DL, Connor JM, Pyeritz RE, eds. Principles and Practice of Medical Genetics. 3rd edn. New York: Churchill Livingstone, 1997:1027-66.
3. Marfan MA-B. Un cas de deformation congenitale des quatre membres, plus prononcee aux extremites, caracterisee par l'allongement des os avec un certain degre d'amincissement. Bull Mem Soc Med Hop Paris 1896;13:220-6.
4. Etter LE, Glover LP. Arachnodactyly complicated by dislocated lens and death from rupture of dissecting aneurysm of aorta. JAMA 1943;123:88-9.
5. Murdoch JL, Walker BA, Halpern BL, Kuzma JW, McKusick VA. Life expectancy and causes of death in the Marfan syndrome. N Engl J Med 1972;286:804-8.
6. Hollister DW, Godfrey M, Sakal LY, Pyeritz RE. Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome. N Engl J Med 1990;323:152-9.
7. Kainulainen K, Pulkkinen L, Savolainen A, Kaitila I, Peltonen L, Location on chromosome 15 of the gene defect causing Marfan syndrome. N Engl J Med 1990;323:935-9.
8. Dietz HC, Cutting GR, Pyeritz RE, et al. Defects in the fibrillin gene cause the Marfan syndrome; linkage evidence and identification of a missense mutation. Nature 1991;352:337-9.
9. Biery NJ, Eldadah ZA, Moore CS, Stetten G, Spencer F, Dietz HC. Revised genomic organization of FBN1 and significance for regulated gene expression. Genomics 1999;56:70-7.
10. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003:33:407-11.
11. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312:117-21.
12. Tiecke F, Katzke S, Booms P, et al. Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype-phenotype correlations in FBN1 exons 24-40. Eur J Hum Genet 2001; 9:13-21.
13. Robinson PN, Booms P, Katzke S, et al. Mutations of FBN1 and genotype-phenotype correlations in Marfan syndrome and related fibrillinopathies. Hum Mutat 2002;20:153-61.
14. DePaepe A, Deitz HC, Devereux RB, Hennekem R, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996;62:417-26.
15. Fattori R, Nienaber CA, Descovich B, et al. Importance of dural ectasia in phenotypic assessment of Marfan's syndrome. Lancet 1999;354:910-13.
16. Rose PS, Levy HP, Ahn NU, et al. A comparison of the Berlin and Ghent nosologies and the influence of dural ectasia in the diagnosis of Marfan syndrome. Genet Med 2000;2:278-82.
17. Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 2004;36:855-60.
18. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006;355:788-98.
19. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994;330:1335-41.
20. Rossi-Foulkes R, Roman MJ, Rosen SE, et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol 1999; 83:1364-8.
21. Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 2005;95:1125-7.
22. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 2002;73:17-27.
23. David TE, Feindel CM. An aortic valve-sparing operation for patients with aortic incompetence and aneurysm of the ascending aorta. J Thorac Cardiovasc Surg 1992:103:617-21.
24. De Paulls R, De Matteis GM, Nardi P, et al. One-year appraisal of a new aortic root conduit with sinuses of Valsalva. J Thorac Cardiovasc Surg 2002;123:33-9.
25. Maron BJ, Chaltman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004;109:2807-16.
26. Ageno W, Crotti S, Turpie AG. The safety of antithrombotic therapy during prepancy. Expert Opin Drug Saf 2004;3:113-18.
27. Lev-Ran O, Kramer A, Gurevitch J, Shapira I, Mohr R. Low-molecular-weight heparin for prosthetic heart valves: treatment failure. Ann Thorac Surg 2000;69:264-5.
28. Meijboom LJ, Vos. FE, Timmermans J, et al. Pregnancy and aortic root growth in the Marfan syndrome: a prospective study. Eur Heart J 2005;26:914-29.